Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Part of paid clinical trials in Miami, Florida.

Sponsor
University of Miami
Study ID
NCT07217678
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durysta, Bimatoprost Intracameral Implant 10 µg — DRUG
    Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.

Study Details

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Key Dates

Start date
Feb 9, 2026
Status verified
Mar 2026
Primary completion
Jan 31, 2028
Completion
Jan 31, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durysta
    Participants will receive a one-time intracameral administration of Durysta - bimatoprost 10mcg

Primary Outcome Measure

Change in Caspase-1 mRNA Expression Following Durysta Injection [ Time Frame: Baseline, post-injection 1 month, post-injection 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Bascom Palmer Eye InstituteMiamiFlorida33134
Javier Paredes, BA, MBA
[email protected]
305-326-6387
Monica Arango, BA
[email protected]
305-326-6351
Swarup S Swaminathan, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Miami, FL

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Bascom Palmer Eye Institute· Miami, FL

Related Studies